Vera Therapeutics, Inc. (VERA)

Market Cap	2.49B +77.1%
Revenue (ttm)	n/a
Net Income	-368.95M
EPS	-5.57
Shares Out	71.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	870,612
Open	33.42
Previous Close	33.25
Day's Range	33.42 - 34.88
52-Week Range	18.76 - 56.05
Beta	0.95
Analysts	Strong Buy
Price Target	78.29 (+126.14%)
Earnings Date	May 7, 2026

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 249
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Summary

According to 14 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $78.29, which is an increase of 126.14% from the latest price.

Price Target

$78.29

(126.14% upside)

Analyst Consensus: Strong Buy